Supernus Pharmaceuticals (SUPN)
(Real Time Quote from BATS)
$28.93 USD
+0.31 (1.08%)
Updated Jul 15, 2024 01:30 PM ET
3-Hold of 5 3
B Value A Growth C Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SUPN 28.93 +0.31(1.08%)
Will SUPN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SUPN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SUPN
Do Options Traders Know Something About Supernus (SUPN) Stock We Don't?
Compared to Estimates, Supernus (SUPN) Q1 Earnings: A Look at Key Metrics
SUPN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ahead of Supernus (SUPN) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Supernus (SUPN) Reports Q4 Earnings: What Key Metrics Have to Say
Supernus Pharmaceuticals (SUPN) Lags Q4 Earnings Estimates
Other News for SUPN
Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
Wall Street Analysts Are Bullish on Top Healthcare Picks
Stifel Nicolaus Sticks to Its Hold Rating for Supernus Pharmaceuticals (SUPN)
Piper Sandler Sticks to Its Buy Rating for Supernus Pharmaceuticals (SUPN)
Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy